FDA approvals outrun staff cuts: 23 novel drugs mark the best first half in three years – Endpoints News

FDA approvals outrun staff cuts: 23 novel drugs mark the best first half in three years  Endpoints NewsFDA authorizes more devices so far in 2026, but it’s taking longer  MedTech DiveRegulatory Actions for June 2026  PharmTech.comThe June 2026 Shift: US FDA Approvals Redefining Global Standards  drugscontrol.orgDespite chaos and churn, FDA decisions hold mostly steady in H1 2026  BioSpace